- 53.6% of VEREGEN® patients demonstrated complete clearance of EGW vs 35.3% for vehicle1
- 93.2% of VEREGEN® patients with complete clearance of EGW experienced sustained clearance at 12 weeks posttreatment vs 94.2% for vehicle1
- The most common adverse reactions are local skin and application site reactions including (incidence ≥ 20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and vesicular rash1
- The incidence of patients with adverse events leading to discontinuation was 2.3%2
- In the overall study population, the severity of erythema, erosion, edema, and induration was maximal at Week 2 of treatment1
VEREGEN® is indicated for the topical treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older.
Important Safety InformationVEREGEN® has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds.
Avoid exposure of VEREGEN®-treated areas to sun/UV-light because VEREGEN® has not been tested under these circumstances. Safety and efficacy of VEREGEN® have not been established in immunosuppressed patients or patients under 18 years of age, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.
The most common adverse reactions are local skin and application site reactions including (incidence ≥ 20%) erythema, pruritus, burning, pain/discomfort, erosion/ulceration, edema, induration, and vesicular rash.
VEREGEN® (sinecatechins) Ointment, 15% Full Prescribing Information.